Polymorphs of thyroid hormone receptor agonists and their uses
Patent Information
- Application Number
- TW112104239
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2023-01-04
- Filing Date
- 2023-02-07
- Publication Date
- 2026-11-01
- Estimated Expiration
- 2043-02-06
AI Technical Summary
Existing thyroid hormone receptor agonists lack suitable pharmaceutical crystal forms that provide stability, hygroscopicity, and efficacy, making them unsuitable for effective pharmaceutical use.
Development of polymorphic forms of thyroid hormone receptor agonists with high purity, good solubility, and resistance to high temperature, humidity, and light, including specific crystal forms such as A, B, C, and others, characterized by unique X-ray powder diffraction patterns and thermal stability.
The polymorphic forms exhibit improved physical and chemical properties, enhancing stability, reducing filtration time, and increasing bioavailability, ensuring the safety and effectiveness of the medication by preventing degradation under various environmental conditions.
Smart Images

Figure TWG2TB001918418_001 
Figure TWG2TB001918418_002 
Figure TWG2TB001918418_003
Abstract
Description
Polymorphs of thyroid hormone receptor agonists and their uses This invention belongs to the pharmaceutical field and relates to polymorphs of thyroid hormone receptor agonists, their preparation methods, and uses. Familial hypercholesterolemia (FH) is a classic autosomal (co-)dominant genetic disorder, primarily characterized by significantly elevated serum low-density lipoprotein cholesterol (LDL-C) levels and xanthoma of the skin / tendons, which can lead to early-onset cardiovascular disease. Common types of FH include heterozygous familial hypercholesterolemia (HeFH) and the rarer homozygous familial hypercholesterolemia (HoFH). Statistics show that the prevalence of HeFH is as high as 0.2%-0.48%. FH is usually caused by mutations in the inactivation of the LDL receptor (LDLR). Clinically, statins are the first-line treatment, not only lowering LDL-C levels but also improving the prognosis of FH patients. Patients who do not respond well to statins or experience adverse reactions can be treated with the cholesterol absorption inhibitor ezetimibe. For patients whose treatment still does not achieve the desired results, a PCSK9 inhibitor can be added. Although there are treatments available for HeFH, many patients (up to 40% of HeFH patients) still cannot achieve target cholesterol (LDL-C) levels after these treatments, and the accumulation of cholesterol in their bodies becomes a lifelong burden. Thyroid hormone receptors are divided into α and Two subtypes, beta and β. Thyroid hormones and... The binding of the β-receptor can promote cholesterol metabolism. Based on this, a variety of selective agonists have been developed in recent years. Beta-subtype thyroid hormone analogs or thyroxine-like drugs. MGL-3196, an oral agonist developed by Madrigal, has shown in clinical results to significantly reduce in vivo LDL-C levels, improve metabolic syndromes (such as insulin resistance and dyslipidemia), and fatty liver disease (including lipotoxicity and inflammation). Patent WO2019240938A1 describes the compound (R)-2-(3,5-dichloro-4-((7-(methyl-d3)-1-sideoxy-2,5,6,7-tetrahydro-1H-cyclopentane[d]tadalafil). -4-yl)oxy)phenyl)-3,5-dioxy-2,3,4,5-tetrahydro-1,2,4-tris( ...tetrahydro-1,2,4-tris(2,3,4,5-tetrahydro-1,2,4-tetrahydro-1,2,4-tris(2,3,4,5- 6-Formonitrile, belonging to the β-receptor agonists of thyroxine, is intended for the treatment of primary hypercholesterolemia, and its preparation method has been disclosed. However, developing pharmaceutically suitable crystal forms for the compound, especially those that improve stability, hygroscopicity, shelf life, and / or efficacy, to achieve better results in pharmaceutical manufacturing, remains an urgent problem to be solved. The present invention provides a polymorph of the compound of formula I, which has excellent properties such as high purity, good solubility, stable physical and chemical properties, resistance to high temperature, high humidity and strong light, and low hygroscopicity. Polymorphs of Formula I compounds: Where n is 0~2, and X is H 2O, 4-methyl-2-pentanone, toluene, DMF, acetone, ethyl acetate, DMSO, isopropyl acetate, dioxane, acetonitrile, tetrahydrofuran, or ethylene glycol monomethyl ether. In some implementations, n is 0 to 2. In some implementations, n is 0 to 1. In some implementations, X is H 2O. In some implementations, n is 2 and X is H. 2O, the polymorph is crystal form A, and its X-ray powder diffraction pattern, when subjected to Cu-Kα radiation, has characteristic diffraction peaks at the following 2θ positions: 5.68°±0.2°, 11.44°±0.2°, 17.19°±0.2°, 24.94°±0.2°, 26.40°±0.2°, and 29.47°±0.2°. Furthermore, the crystal form A also has characteristic diffraction peaks at the following 2θ positions in its X-ray powder diffraction pattern: 12.68°±0.2°, 19.44°±0.2°, 19.79°±0.2°, and 23.27°±0.2°. Furthermore, the crystal form A has a characteristic diffraction peak at the following 2θ position in its X-ray powder diffraction pattern: Furthermore, the X-ray powder diffraction pattern of the crystal form A is basically as shown in Figure 1. Furthermore, the crystal form A has the DSC diagram and / or TGA diagram shown in Figure 2. In some embodiments, n is 0.4, X is 4-methyl-2-pentanone, the polymorph is crystal form B, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 8.03°±0.2°, 11.05°±0.2°, 11.82±0.2°, 16.14±0.2°, 16.55°±0.2°, 22.01°±0.2°, 22.34°±0.2°, 23.43±0.2°, 24.34±0.2°, 25.18°±0.2°, and 29.30°±0.2°. Furthermore, the crystal form B has a characteristic diffraction peak at the following 2θ position in its X-ray powder diffraction pattern: Furthermore, the X-ray powder diffraction pattern of the crystal form B is basically as shown in Figure 3. Furthermore, the crystal form B has the DSC diagram and / or TGA diagram shown in Figure 4. In some embodiments, n is 0, the polymorph is crystal form C, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 11.03°±0.2°, 15.79°±0.2°, 16.97°±0.2°, 23.27°±0.2°, 23.76°±0.2°, and 27.61°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form C also has characteristic diffraction peaks at the following 2θ positions: 14.12°±0.2°, 19.73°±0.2°, 22.51°±0.2°, 25.37°±0.2°, 28.21°±0.2°, and 33.73°±0.2°. Furthermore, the crystal form C has a characteristic diffraction peak at the following 2θ position in its X-ray powder diffraction pattern: Furthermore, the X-ray powder diffraction pattern of the crystal form C is basically as shown in Figure 5. Furthermore, the crystal form C has the DSC diagram and / or TGA diagram shown in Figure 6. In some embodiments, n is 0.4, X is toluene, the polymorph is crystal form D, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 5.93±0.2°, 11.90°±0.2°, 13.38°±0.2°, 15.50°±0.2°, 16.84°±0.2°, 17.91°±0.2°, 18.51°±0.2°, 20.24°±0.2°, 20.86°±0.2°, 23.95°±0.2°, 26.25°±0.2°, 29.94°±0.2°, 32.48°±0.2°, and 36.29°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form D is basically as shown in Figure 7. Furthermore, the crystal form D has the DSC diagram and / or TGA diagram shown in Figure 8. In some embodiments, n is 0.8, X is DMF, the polymorph is crystal form E, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 4.75°±0.2°, 5.76°±0.2°, 8.23°±0.2°, 9.47°±0.2°, 10.83°±0.2°, 14.21°±0.2°, 16.43°±0.2°, 18.43°±0.2°, 18.70°±0.2°, 19.02°±0.2°, 22.84°±0.2°, and 26.42°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form E is basically as shown in Figure 9. Furthermore, the crystal form E has the DSC diagram and / or TGA diagram shown in Figure 10. In some embodiments, n is 1, X is acetone, the polymorph is crystal form F, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 6.67°±0.2°, 7.65°±0.2°, 8.34°±0.2°, 10.17°±0.2°, 12.37±0.2°, 13.42°±0.2°, 15.48°. °±0.2°, 18.49±0.2°, 19.05°±0.2°, 20.47°±0.2°, 21.64°±0.2°, 22.86°±0.2°, 23.17°±0.2°, 23.41°±0.2°, 24.88°±0.2°, 28.15°±0.2°, 28.75°±0.2°, 32.85°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form F is basically as shown in Figure 11. Furthermore, the crystal form F has the DSC diagram and / or TGA diagram shown in Figure 12. In some embodiments, n is 1, X is ethyl acetate, the polymorph is crystal form G, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 8.69°±0.2°, 9.14°±0.2°, 11.03°±0.2°, 11.88°±0.2°, 12.62°±0.2°, 13.53°±0.2°, 16.14°±0.2°, 16.66°±0.2°, 16.94°±0.2°. 2°, 17.40°±0.2°, 18.70°±0.2°, 18.82°±0.2°, 19.19°±0.2°, 20.73°±0.2°, 22.82°±0.2°, 23.76°±0.2°, 24.15°±0.2°, 24.36°±0.2°, 24.79°±0.2°, 25.60°±0.2°, 26.28°±0.2°, 27.16°±0.2°, 29.41°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form G is basically as shown in Figure 13. Furthermore, the crystal form G has the DSC diagram and / or TGA diagram shown in Figure 14. In some embodiments, n is 1, X is DMSO, the polymorph is crystal form H, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 5.53°±0.2°, 8.54°±0.2°, 11.05°±0.2°, 16.59°±0.2°, 18.16°±0.2°, 21.04°±0.2°, 21.91°±0.2°, 22.16°±0.2°, 22.75°±0.2°, 23.45°±0.2°, 25.70°±0.2°, 26.65°±0.2°, and 27.57°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form H is basically as shown in Figure 15. Furthermore, the crystal form H has the DSC diagram and / or TGA diagram shown in Figure 16. In some embodiments, n is 0.9, X is isopropyl acetate, the polymorph is crystal form I, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 8.36°±0.2°, 10.17°±0.2°, 11.36°±0.2°, 12.72°±0.2°, 13.20°±0.2°, 16.55°±0.2°, 16.78°±0.2°, 17.13°±0.2°, 18.92°±0.2°, 19.85°±0.2°, 23.50°±0.2°, 23.97°±0.2°, 24.50°±0.2°, 25.60°±0.2°, 26.79°±0.2°, and 30.00°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form I is basically as shown in Figure 17. Furthermore, the crystal form I has the DSC diagram and / or TGA diagram shown in Figure 18. In some embodiments, X is acetonitrile, the polymorph is crystal form J, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 10.07°±0.2°, 11.07°±0.2°, 11.53°±0.2°, 13.34°±0.2°, 14.08°±0.2°, 14.23°±0.2°, 14.51°±0.2°, 14.99°±0.2°, 15.17°±0.2°, 15.56°±0.2°, 15.83°±0.2°, 16.02°±0.2°, 16.70°. ±0.2°, 16.99°±0.2°, 17.75°±0.2°, 17.97°±0.2°, 18.35°±0.2°, 19.00°±0.2°, 20.10°±0.2°, 21.97°±0.2°, 22.47°±0.2°, 23.27°±0.2°, 24.11°±0.2°, 24.75°±0.2°, 25.60°±0.2°, 26.32°±0.2°, 27.29°±0.2°, 27.74°±0.2°, 28.66°±0.2°, 29.45°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form J is basically as shown in Figure 19. Furthermore, the crystal form J has the DSC diagram and / or TGA diagram shown in FIG20. In some embodiments, n is 0.9, X is dioxane, the polymorph is crystal form K, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 7.63°±0.2°, 8.34°±0.2°, 22.26°±0.2°, 23.04°±0.2°, and 23.27°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form K is basically as shown in Figure 21. Furthermore, the crystal form K has the DSC diagram and / or TGA diagram shown in Figure 22. In some implementations, n is 2 and X is H. 2O, the polymorph is of crystal form L, and when subjected to Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 5.72°±0.2°, 11.49°±0.2°, 12.56°±0.2°, 14.33°±0.2°, 17.32°±0.2°, 25.33°±0.2°, 26.25°±0.2°. Furthermore, the crystal form L has a characteristic diffraction peak at the following 2θ position in its X-ray powder diffraction pattern: Furthermore, the X-ray powder diffraction pattern of the crystal form L is basically as shown in Figure 23. Furthermore, the crystal form L has the DSC diagram and / or TGA diagram shown in Figure 24. In some embodiments, the polymorph is crystal form M, and its X-ray powder diffraction pattern, when subjected to Cu-Kα radiation, exhibits characteristic diffraction peaks at the following 2θ positions: 4.73°±0.2°, 5.24°±0.2°, 6.56°±0.2°, 7.53°±0.2°, 8.31°±0.2°, 18.84°±0.2°, 21.48°±0.2°, and 22.88°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form M is basically as shown in Figure 25. Furthermore, the crystal form M has the DSC diagram and / or TGA diagram shown in Figure 26. In some embodiments, n is 0.6, X is acetonitrile, the polymorph is crystalline N, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 8.42°±0.2°, 9.08°±0.2°, 10.85°±0.2°, 16.86°±0.2°, and 17.23°±0.2°. Furthermore, the crystal form N has a characteristic diffraction peak at the following 2θ position in its X-ray powder diffraction pattern: Furthermore, the X-ray powder diffraction pattern of the crystal form N is basically as shown in Figure 27. Furthermore, the crystal form N has the DSC diagram and / or TGA diagram shown in FIG28. In some embodiments, n is 0.8, X is DMF, the polymorph is crystal form O, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 5.49°±0.2°, 8.64°±0.2°, 10.89°±0.2°, 11.45°±0.2°, 16.37°±0.2°, 18.55°±0.2°, 21.44°±0.2°, 22.14°±0.2°, 22.73°±0.2°, 22.98°±0.2°, 23.25°±0.2°, and 26.17°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form O is basically as shown in Figure 29. Furthermore, the crystal form O has the DSC diagram and / or TGA diagram shown in FIG30. In some implementations, n is 2 and X is H. 2O, the polymorph is of crystal form P, and when irradiated with Cu-Kα, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 5.76°±0.2°, 11.55°±0.2°, 17.38°±0.2°, 23.12°±0.2°, 24.50°±0.2°, 26.58°±0.2°. Furthermore, the crystal form P also has characteristic diffraction peaks at the following 2θ positions in its X-ray powder diffraction pattern: 14.60°±0.2°, 17.13°±0.2°, 25.90°±0.2°, and 29.48°±0.2°. Furthermore, the crystal form P has a characteristic diffraction peak at the following 2θ position in its X-ray powder diffraction pattern: Furthermore, the X-ray powder diffraction pattern of the crystal form P is basically as shown in Figure 31. Furthermore, the crystal form P has the DSC diagram and / or TGA diagram shown in Figure 32. In some embodiments, X is water and tetrahydrofuran, the polymorph is crystal form Q, and Cu-Kα radiation is used, with its X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ positions: 7.55°±0.2°, 8.25°±0.2°, 10.09°±0.2°, 12.29°±0.2°, 15.42°±0.2°, 18.47°±0.2°, 18.96°±0.2°, 22.16°±0.2°, 22.90°±0.2°, 23.17°±0.2°, 23.54°±0.2°, 24.07°±0.2°, 24.79°±0.2°, and 25.97°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form Q is basically as shown in Figure 33. Furthermore, the crystal form Q has the DSC diagram and / or TGA diagram shown in Figure 34. In some embodiments, n is 0.9, X is dioxane, the polymorph is crystal form R, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 7.53°±0.2°, 8.25°±0.2°, 10.07°±0.2°, 13.32°±0.2°, 15.32°±0.2°, 18.33°±0.2°, 22.14°±0.2°, 22.82°±0.2°, and 23.14°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form R is basically as shown in Figure 35. Furthermore, the crystal form R has the DSC diagram and / or TGA diagram shown in FIG36. In some embodiments, n is 1, X is DMSO, the polymorph is crystal form S, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 7.74°±0.2°, 8.46°±0.2°, 10.29°±0.2°, 12.37°±0.2°, 13.55°±0.2°, 15.61°±0.2°, 18.65°±0.2°, 19.09°±0.2°, 23.23°±0.2°, 23.49°±0.2°, and 24.79°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form S is basically as shown in Figure 37. Furthermore, the crystal form S has the DSC diagram and / or TGA diagram shown in FIG38. In some embodiments, n is 1, X is 4-methyl-2-pentanone, the polymorph is crystal form T, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 6.81°±0.2°, 6.98°±0.2°, 7.78°±0.2°, 9.76°±0.2°, 11.82°±0.2°, 13.65°±0.2°, 15.36°±0.2°, 17.42°±0.2°, 18.26°±0.2°, 18.51°±0.2°, 21.78°±0.2°, 22.22°±0.2°, 23.82°±0.2°, 25.04°±0.2°, and 28.52°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form T is basically as shown in Figure 39. Furthermore, the crystal form T has the DSC diagram and / or TGA diagram shown in FIG40. In some embodiments, n is 1, X is acetonitrile, the polymorph is crystal form U, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 7.72°±0.2°, 8.42°±0.2°, 18.63°±0.2°, 23.25°±0.2°, and 23.49°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form U is basically as shown in Figure 41. Furthermore, the crystal form U has the DSC diagram and / or TGA diagram shown in Figure 42. In some embodiments, n is 0, the polymorph is crystal form V, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 7.41°±0.2°, 11.05°±0.2°, 15.81°±0.2°, 16.97°±0.2°, 22.53°±0.2°, 23.29°±0.2°, and 27.63°±0.2°. Furthermore, the crystal form V also has characteristic diffraction peaks at the following 2θ positions in its X-ray powder diffraction pattern: 14.16°±0.2°, 15.59°±0.2°, 19.73°±0.2°, 21.33°±0.2°, 23.78°±0.2°, 25.39°±0.2°, and 33.75°±0.2°. Furthermore, the crystal form V has a characteristic diffraction peak at the following 2θ position in its X-ray powder diffraction pattern: Furthermore, the X-ray powder diffraction pattern of the crystal form V is basically as shown in Figure 43. Furthermore, the crystal form V has the DSC diagram and / or TGA diagram shown in FIG44. In some embodiments, n is 0.7, X is ethylene glycol monomethyl ether, the polymorph is crystalline form W, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 6.69°±0.2°, 7.51°±0.2°, 8.31°±0.2°, 10.17°±0.2°, 12.48°±0.2°, 13.46°±0.2°, 15°±0.2°. 0.52°±0.2°, 18.28°±0.2°, 18.55°±0.2°, 22.20°±0.2°, 22.79°±0.2°, 23.17°±0.2°, 23.89°±0.2°, 24.42°±0.2°, 25.10°±0.2°, 26.65°±0.2°, 28.01°±0.2°, 28.29°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form W is basically as shown in Figure 45. In some embodiments, the polymorph is crystal form X, and its X-ray powder diffraction pattern, when subjected to Cu-Kα radiation, exhibits characteristic diffraction peaks at the following 2θ positions: 5.99°±0.2°, 10.52°±0.2°, 11.16°±0.2°, 12.21°±0.2°, 15.71°±0.2°, 16.41°±0.2°, 18.02°±0.2°, 19.95°±0.2°, 21.91°±0.2°, 22.32°±0.2°, and 26.05°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form X is basically as shown in Figure 46. In some embodiments, the polymorph is of crystal form Y, and its X-ray powder diffraction pattern, when subjected to Cu-Kα radiation, exhibits characteristic diffraction peaks at the following 2θ positions: 3.21°±0.2°, 3.23°±0.2°, 7.66°±0.2°, 8.36°±0.2°, 9.08°±0.2°, 10.25°±0.2°, 12.43°±0.2°, 18.61°±0.2°, 19.03°±0.2°, 22.98°±0.2°, 23.27°±0.2°, 23.70°±0.2°, 24.92°±0.2°, and 26.13°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form Y is basically as shown in Figure 47. In some embodiments, n is 0.9, X is DMF, the polymorph is crystal form Z, and Cu-Kα radiation is used. Its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 8.34°±0.2°, 10.17°±0.2°, 11.40°±0.2°, 13.51°±0.2°, 14.84°±0.2°, 18.28°±0.2°, 18.76°±0.2°, 20.16°±0.2°, 20.45°±0.2°, 20.73°±0.2°, 21.15°±0.2°, 24.71°±0.2°, 25.99°±0.2°, 26.50°±0.2°, 26.79°±0.2°, and 30.04°±0.2°. Furthermore, the X-ray powder diffraction pattern of the crystal form Z is basically as shown in Figure 48. Furthermore, the crystal form Z has the DSC diagram and / or TGA diagram shown in Figure 49. The present invention also provides a pharmaceutical composition comprising any one of the aforementioned polymorphs A to Z, and a pharmaceutically acceptable carrier and / or excipient. In some examples, the pharmaceutical composition comprises any one of the aforementioned polymorphs A, C, L, P, V, and a pharmaceutically acceptable carrier and / or excipient. The present invention also provides the use of any of the aforementioned polymorphs A to Z, or compositions containing them, in the preparation of medicines for treating diseases mediated by thyroid hormone receptor β. In some examples, the use of any of the aforementioned polymorphs A, C, L, P, and V, or compositions containing them, in the preparation of medicines for treating diseases mediated by thyroid hormone receptor β is provided. Furthermore, the disease mediated by the thyroid hormone receptor β is primary hypercholesterolemia. The polymorphs of crystal forms A to Z described in this invention are present at about 5% to about 100% by weight of the active pharmaceutical ingredient; in some instances, they are present at about 10% to about 100% by weight of the active pharmaceutical ingredient. It is present in % by weight; in some instances, it is present in about 15% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 20% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 25% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 30% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 35% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 40% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 45% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 50% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 55% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 60% by weight to about 100% by weight of the active pharmaceutical ingredient. It is present in the following amounts: in some instances, it is present in about 65% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 70% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 75% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 80% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 85% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 90% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 95% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 98% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, it is present in about 99% by weight to about 100% by weight of the active pharmaceutical ingredient; in some instances, substantially all of the active pharmaceutical ingredient is essentially pure crystal. The present invention also provides a method for preparing any one of the polymorphs from crystal form A to crystal form Z, comprising: (1) Suspension method: Add the crude free base of compound I (which can be prepared according to the method described in WO2019240938A1) to a selected single-membered or two-membered solvent until a suspension is formed. After suspending and stirring at room temperature to 50°C for a certain period of time (e.g., 1h~3 days, 2h~24h, 2h~12h, or 3~5h), centrifuge the suspension, and dry it to obtain the product; or (2) Dissolution-precipitation crystallization method: The crude free base of compound I is completely dissolved in an appropriate amount of good solvent. A certain amount of the solution is then added dropwise to a poor solvent, or the poor solvent is added dropwise to the solution. The solid is stirred and precipitated, then dried separately to obtain the product; or (3) Cooling method: At 50~80℃, add the crude free base of compound I to an appropriate amount of solvent until the solid is just completely dissolved. Transfer the solution to room temperature to cool, allow to stand or stir to crystallize, separate the crystals, and dry to obtain the product; or (4) Gas-phase diffusion method: A certain amount of the crude free base of compound I is added dropwise to a suitable amount of good solvent at room temperature to completely dissolve the sample or to prepare a saturated solution of good solvent; a certain amount of solution is taken separately, and the clear solution is placed in a poor solvent atmosphere and allowed to stand at room temperature until a solid precipitates out, which is then isolated to obtain the product; or (5) Thermal transfer method: Take a certain amount of sample and place it on a glass ingot on a hot table. Heat it to the target temperature at a certain rate (e.g., 5~20℃ / min, or 10~15℃ / min) and keep it at a constant temperature for a period of time (e.g., 0.5~5min, or 1~3min, or 1~2min). Then cool it down naturally to room temperature to obtain a solid. The terms "good solvent" and "bad solvent" in this invention are relative. In a pair of solvents, the one with higher solubility is considered a good solvent, and the one with lower solubility is considered a bad solvent. In some embodiments, the good solvent is selected from those with higher solubility among ethylene glycol methyl ether, ethylene glycol dimethyl ether, dioxane, DMF, DMSO, methanol, ethanol, n-propanol, butyl formate, 4-methyl-2-pentanone, tetrahydrofuran, isopropanol, ethyl acetate, n-heptane, diethyl ether, water, acetonitrile, toluene, chloroform, acetone, butyl formate, MTBE, and cyclohexane, while the bad solvent is selected from those with lower solubility. In some embodiments, the good solvent is selected from ethylene glycol methyl ether, ethylene glycol dimethyl ether, dioxane, DMF, DMSO, methanol, ethanol, n-propanol, butyl formate, 4-methyl-2-pentanone, tetrahydrofuran, or mixtures thereof. In some embodiments, the undesirable solvent is selected from isopropanol, ethyl acetate, n-heptane, diethyl ether, water, acetonitrile, toluene, chloroform, acetone, butyl formate, MTBE, cyclohexane, or mixtures thereof. Unless otherwise specified, the solvents used in the above five preparation methods may be a single solvent or a combination of two or more solvents. In some instances, the solvent for suspension is chloroform; in some instances, the solvent for suspension is tetrahydrofuran; in some instances, the solvent for suspension is a combination of 4-methyl-2-pentanone and cyclohexane; in some instances, the solvent for suspension is isopropyl acetate; in some instances, the solvent for suspension is acetonitrile; in some instances, the solvent for suspension is chloroform and ethanol; in some instances, the solvent for suspension is toluene; and in some instances, the solvent for suspension is water and DMF. In some instances, the solvents used in the solution-precipitation crystallization method are ethylene glycol methyl ether and toluene; in some instances, DMF and water; in some instances, ethylene glycol monomethyl ether and acetone; in some instances, dioxane and diethyl ether; in some instances, ethylene glycol methyl ether and ethyl acetate; in some instances, DMSO and water; in some instances, dioxane and n-heptane; in some instances, dioxane and water; and in some instances, ethylene glycol dimethyl ether and chloroform. In some instances, the solvents used in the cooling method are ethanol and DMSO; in some instances, the solvents used in the cooling method are acetonitrile and methanol; in some instances, the solvents used in the cooling method are ethylene glycol dimethyl ether and acetonitrile; in some instances, the solvents used in the cooling method are methanol and DMF; and in some instances, the solvents used in the cooling method are toluene and methanol. In some instances, the gas-phase diffusion method employs the gas-phase diffusion of an ethylene glycol monomethyl ether solution in diethyl ether. The present invention has the following beneficial effects: The crystal form of this invention possesses excellent physicochemical properties. For example, its good flowability and significantly improved adhesion allow for a marked reduction in filtration time during formulation, shortening the production cycle and saving costs. Its good light stability, thermal stability, and humidity stability ensure the reliability of the crystal form during storage and transportation, thereby guaranteeing the safety of the formulation and its effectiveness after long-term storage. Furthermore, the crystal form does not require special packaging to prevent the effects of light, temperature, and humidity, thus reducing costs. The crystal form does not degrade due to light, high temperature, or high humidity, so patients taking the crystal form do not need to worry about photosensitivity reactions caused by exposure to sunlight. The crystal form also has high solubility, which is beneficial for drug dissolution and improves bioavailability. The polymorphs of this invention, particularly polymorph C, are XRPD results showing to be highly crystalline solids with excellent stability. They exhibit high melting points, good thermal stability, and no crystal form transformation under high temperature, high humidity, light, or accelerated conditions. Multiple polymorphs, after transformation, yield a more stable polymorph C, which is virtually non-hygroscopic. This makes it highly useful as an active ingredient in pharmaceutical preparations. It remains stable even when stored above room temperature and during high-temperature formulation preparation. It is understandable that differential scanning calorimetry (DSC) is well-known in the industry. The melting peak of a DSC curve depends on many factors related to sample preparation and instrument geometry, while the peak position is relatively insensitive to experimental details. Therefore, in some instances, the crystalline compounds of this invention have DSC plots with characteristic peak positions that have substantially the same properties as the DSC plots provided in the accompanying drawings, with a measurement error tolerance of ±5°C, generally required to be within ±3°C. It is understood that the values described and protected in this invention are approximate. Variations within these values may be attributed to equipment calibration, equipment error, purity of crystals, crystal size, sample size, and other factors. It is understood that the crystal form of the present invention is not limited to the characteristic spectra that are exactly the same as those described in the accompanying drawings disclosed in the present invention, such as XRPD, DSC, TGA, DVS, and isothermal adsorption curves. Any crystal form that has a characteristic spectra that are substantially the same or essentially the same as those described in the accompanying drawings falls within the scope of the present invention. "Therapeutic effective amount" refers to the amount of a compound that elicits a physiological or medical response in an tissue, system, or subject. This amount is sought to include, when administered to a subject, the amount of a compound sufficient to prevent or reduce to some degree one or more symptoms of the disease or condition being treated. Room temperature: 10℃~30℃. "Carrier" refers to a system that does not cause significant stimulation to an organism and does not eliminate the biological activity and properties of the given compound, and can change the way a drug enters the human body and its distribution in the living body, control the release rate of the drug, and deliver the drug to the target organ. Non-limiting examples include microcapsules and microspheres, nanoparticles, liposomes, etc. "Excipient" means an agent that is not itself a therapeutic agent but is used as a diluent, excipient, binder, and / or medium to be added to a pharmaceutical composition to improve its handling or storage properties or to allow or promote the formation of a unit dosage form of the compound or pharmaceutical composition for administration. As is known to those skilled in the art, pharmaceutical excipients can provide a variety of functions and can be described as wetting agents, buffers, suspending agents, lubricants, emulsifiers, disintegrants, absorbents, preservatives, surfactants, colorants, flavoring agents, and sweeteners. Examples of pharmaceutical excipients include, but are not limited to: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, cellulose acetate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, microcrystalline cellulose and croscarmellose (e.g. croscarmellose sodium); (4) tragacanth gum powder; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter. (9) Oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) Diols, such as propylene glycol; (11) Polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) Esters, such as ethyl oleate and ethyl laurate; (13) Agar; (14) Buffers, such as magnesium hydroxide and aluminum hydroxide; (15) Alginate; (16) Atherless water; (17) Isotonic saline; (18) Ringer's solution; (19) Ethanol; (20) pH buffer solution; (21) Polyesters, polycarbonates and / or polyanhydrides; and (22) Other non-toxic and compatible substances used in pharmaceutical preparations. "Crystal form" or "crystalline" or "polymorphic" refers to any solid substance that exhibits a three-dimensional arrangement. In contrast to amorphous solid substances, it produces characteristic XRPD patterns with clearly defined peaks. "X-ray powder diffraction pattern (XRPD pattern)" refers to the diffraction pattern observed in experiments or the parameters, data or values derived from it. XRPD patterns are usually characterized by peak position (x-axis) and / or peak intensity (y-axis). "2" "θ" refers to the peak position, expressed in degrees (°), set in an X-ray diffraction experiment, and is usually the horizontal axis unit in a diffraction pattern. If the incident beam forms a peak position with a certain lattice plane... If the reflection is diffracted at an angle θ, then the experimental setup needs to be 2 The θ angle records the reflected beam. It should be understood that the specific 2 of the specific crystal form mentioned in this article... The θ value is intended to represent the value measured using the X-ray diffraction experimental conditions described in this paper. θ value (expressed in degrees). The term "substantially similar" or "substantially as shown in Figure XX" for X-ray diffraction peaks means that representative peak positions and intensity variations are taken into account. For example, those familiar with this technique will understand peak positions (2 θ) will show some variation, typically up to 0.1-0.2°, and the instrument used to measure diffraction will also cause some variation. In addition, those skilled in this technique will understand that relative peak intensities will vary due to differences between instruments, as well as the degree of crystallinity, preferred orientation, the surface of the prepared sample, and other factors known to those skilled in this technique, and should be regarded as qualitative measurements only. Figure 1 shows the X-ray powder diffraction pattern of crystal form A of the compound represented by Formula I. Figure 2 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form A of the compound shown in Formula I. Figure 3 shows the X-ray powder diffraction pattern of crystal form B of the compound represented by Formula I. Figure 4 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form B of the compound shown in Formula I. Figure 5 shows the X-ray powder diffraction pattern of crystal form C of the compound represented by Formula I. Figure 6 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form C of the compound shown in Formula I. Figure 7 shows the X-ray powder diffraction pattern of crystal form D of the compound represented by Formula I. Figure 8 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form D of the compound shown in Formula I. Figure 9 shows the X-ray powder diffraction pattern of crystal form E of the compound represented by Formula I. Figure 10 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of the crystal form E of the compound shown in Formula I. Figure 11 shows the X-ray powder diffraction pattern of crystal form F of the compound represented by Formula I. Figure 12 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form F of the compound shown in Formula I. Figure 13 shows the X-ray powder diffraction pattern of crystal form G of the compound represented by Formula I. Figure 14 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form G of the compound shown in Formula I. Figure 15 shows the X-ray powder diffraction pattern of crystal form H of the compound represented by Formula I. Figure 16 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form H of the compound shown in Formula I. Figure 17 shows the X-ray powder diffraction pattern of crystal form I of the compound represented by formula I. Figure 18 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form I of the compound shown in Formula I. Figure 19 shows the X-ray powder diffraction pattern of crystal form J of the compound represented by Formula I. Figure 20 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form J of the compound shown in Formula I. Figure 21 shows the X-ray powder diffraction pattern of crystal form K of the compound represented by Formula I. Figure 22 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form K of the compound shown in Formula I. Figure 23 shows the X-ray powder diffraction pattern of crystal form L of the compound represented by Formula I. Figure 24 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form L of the compound shown in Formula I. Figure 25 shows the X-ray powder diffraction pattern of crystal form M of the compound shown in Formula I. Figure 26 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form M of the compound shown in Formula I. Figure 27 shows the X-ray powder diffraction pattern of crystal form N of the compound represented by Formula I. Figure 28 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form N of the compound shown in Formula I. Figure 29 shows the X-ray powder diffraction pattern of crystal form O of the compound represented by Formula I. Figure 30 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form O of the compound shown in Formula I. Figure 31 shows the X-ray powder diffraction pattern of crystal form P of the compound represented by Formula I. Figure 32 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form P of the compound shown in Formula I. Figure 33 shows the X-ray powder diffraction pattern of crystal form Q of the compound represented by Formula I. Figure 34 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of the crystal form Q of the compound shown in Formula I. Figure 35 shows the X-ray powder diffraction pattern of crystal form R of the compound represented by Formula I. Figure 36 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of the crystal form R of the compound shown in Formula I. Figure 37 shows the X-ray powder diffraction pattern of crystal form S of the compound represented by Formula I. Figure 38 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form S of the compound shown in Formula I. Figure 39 shows the X-ray powder diffraction pattern of crystal form T of the compound represented by Formula I. Figure 40 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form T of the compound shown in Formula I. Figure 41 shows the X-ray powder diffraction pattern of crystal form U of the compound represented by Formula I. Figure 42 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of the crystal form U of the compound shown in Formula I. Figure 43 shows the X-ray powder diffraction pattern of crystal form V of the compound represented by Formula I. Figure 44 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form V of the compound shown in Formula I. Figure 45 shows the X-ray powder diffraction pattern of crystal form W of the compound represented by Formula I. Figure 46 shows the X-ray powder diffraction pattern of crystal form X of the compound shown in Formula I. Figure 47 shows the X-ray powder diffraction pattern of crystal form Y of the compound represented by Formula I. Figure 48 shows the X-ray powder diffraction pattern of crystal form Z of the compound represented by Formula I. Figure 49 shows the differential scanning calorimetry curve and thermogravimetric analysis spectrum of crystal form Z of the compound shown in Formula I. Figure 50 DVS pattern of crystal form C. Figure 51 shows the X-ray powder diffraction pattern of crystal form C for stability study. The present invention will be described in detail below through examples. Unless otherwise specified, the experimental methods under known conditions were used in the examples. The examples are provided to better illustrate the invention, but should not be construed as limiting the invention to these examples. Non-essential improvements and adjustments made to the examples by those skilled in the art based on the above description are still within the scope of protection of this invention. The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) are given in units of 10⁻⁶ (ppm). NMR measurements were performed using Bruker Avance III 400 and Bruker Avance 300 NMR spectrometers in the following solvents: deuterated dimethyl monoxide (DMSO-d₆), deuterated chloroform (CDCl₃), and deuterated methanol (CD₃OD). Tetramethylsilane (TMS) was used as the internal standard. MS determination (Agilent 6120B (ESI) and Agilent 6120B (APCI)). The HPLC determination was performed using an Agilent 1260DAD high-performance liquid chromatography system (Zorbax SB-C18 100×4.6mm). XRPD measurements were performed using a Bruker D8 Advance (Bruker, GER) X-ray powder diffractometer. The 2θ scan angle ranged from 3° to 45°, with a scan step of 0.02° and an exposure time of 0.12 seconds. The phototube voltage and current for the test samples were 40 kV and 40 mA, respectively, and the sample disk was a zero-background sample disk. The TGA determination was performed using a TA Discovery 55 (TA, US). 2-5 mg of sample was placed in a pre-equilibrated open aluminum sample pan and automatically weighed inside the TGA furnace. The sample was heated to the final temperature at a rate of 10 °C / min, with nitrogen purging at the sample at 60 mL / min and at the balance at 40 mL / min. The DSC determination was performed using a TA Discovery 2500 (TA, US). 1-2 mg of sample was accurately weighed and placed in a perforated DSC Tzero sample pan. The sample was heated to the final temperature at a rate of 10 °C / min, with nitrogen purging at a rate of 50 mL / min. The known starting materials of this invention can be synthesized using or according to methods known in the industry (such as the method in patent WO2019240938A1), or can be purchased from companies such as Titan Technology, Anaiji Chemical, Shanghai Demo, Chengdu Kelong Chemical, Shaoyuan Chemical Technology, and Bailingwei Technology. Example 1: Preparation of crude free base of compound I Step 1: Preparation of compound b N-(3,5-dichloro-4-((7-(methyl-d3)-1-sideoxy-2,5,6,7-tetrahydro-1H-cyclopentane[d]ta -4-yl)oxy)phenyl)benzamide (1H) N-(3,5-dichloro-4-((7-(methyl-d3)-1-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[d]pyridazin-4-yl)oxy)phenyl)benzamid 4.62 kg of compound a was dissolved in 25.0 L of glacial acetic acid and added to a 100 L reactor. 3300 g of benzoic anhydride was added, and the mixture was stirred and reacted at room temperature for about 4 hours. The reaction was monitored by TLC (n-hexane / ethyl acetate = 5 / 1) until compound a disappeared. Then 2722 g of anhydrous sodium acetate was added, and the mixture was heated to 120 °C and stirred for about 18 hours. The reaction solution was cooled to 60-65℃ and concentrated under reduced pressure to remove most of the acetic acid. After concentration, 10L of anhydrous ethanol was added to the residual liquid and mixed thoroughly. Then, the mixture was slowly added to 250L of water while maintaining rapid stirring. A large amount of solid precipitated during the addition process. After the addition was complete, stirring was continued for about 0.5 hours. The mixture was centrifuged, and the filter cake was washed with purified water (20L×2) to obtain compound b. The yield was assumed to be 100%, and the process proceeded directly to the next step. 1H NMR(400MHz,DMSO)δ 12.07(s,1H),10.55(s,1H),8.04(s,2H),7.98-7.95(m,2H),7.63-7.50(m,3H ),3.29-3.25(m,1H),3.02-2.90(m,2H),2.39-2.36(m,1H),1.75-1.72(m,1H). LCMS m / z=433.1[M+1]+ Step 2: Preparation of compound c 4-(4-amino-2,6-dichlorophenoxy)-7-(methyl-d3)-2,5,6,7-tetrahydro-1H-cyclopentyl[d] tadalafil -1-keto 4-(4-amino-2,6-dichlorophenoxy)-7-(methyl-d3)-2,5,6,7-tetrahydro-1H-cyclopenta[d]pyridazin-1-one In a 100L reactor, 5.76kg of the crude product from the previous step, compound b, potassium hydroxide solution (2606g KOH dissolved in 19.5L purified water), and 6.0L of anhydrous ethanol were added with stirring. After the addition was complete, the mixture was heated under reflux for about 16 hours until the reaction of the raw materials was complete. Cool to 25°C, add 30L of water, adjust the pH to 8-9 with ammonium chloride solid, add 35.0L of ethyl acetate and stir. Separate the liquid and extract the aqueous phase with ethyl acetate (15.0L×2). Combine the organic phases and wash with 5% sodium chloride aqueous solution (25L×2). Dry the organic phase with 3.0Kg of anhydrous sodium sulfate, filter, and concentrate the organic phase until no obvious fraction flows out to obtain the crude product. The crude product and 7.0 L of a 10% aqueous solution of dioxane were heated to dissolve the crude product. After cooling to room temperature, the mixture was stirred and crystallized for about 16 hours. The product was filtered to obtain a wet product, which was then purified twice more. The product was then dried under vacuum at 50°C for about 12 hours to obtain compound c 1507 g. 1H NMR(400MHz,DMSO)δ 11.98(s,1H),6.67(m,2H),5.60(s,2H),3.30-3.19(m,1H),3.03-2.93(m,1H),2.90-2.70(m,1H),2.35(m,1H),1.69(m,1H). LCMS m / z=329.0[M+1]+ Step 3: Preparation of compound d (R)-4-(4-amino-2,6-dichlorophenoxy)-7-(methyl-d3)-2,5,6,7-tetrahydro-1H-cyclopentyl[d] tadalafil -1-keto (R)-4-(4-amino-2,6-dichlorophenoxy)-7-(methyl-d3)-2,5,6,7-tetrahydro-1H-cyclopenta[d]pyridazin-1-one 3298g of racemic c was used for palmar separation, and after isolation, two optical isomers were obtained: Compound d (retention time: 1.583 min, 1230 g, off-white solid, ee% = 99.60%, yield 37.3%); Compound d-1 (retention time: 1.926 min, 1255 g, off-white solid, ee%=99.76%, yield 38.1%). Splitting conditions: Instruments: MG Ⅲ preparative SFC; Column: Whelk O1 (S,S), 300×50mm ID, 10μm; Mobile phase: A: CO 2, B: Methanol; Gradient: B 40%; Flow rate: 200 mL / min; Back pressure: 100 bar; Column temperature: 38℃; Wavelength: 220nm; Cycle time: 4.5min; Sample preparation: racemic mixture dissolved in methanol / dichloromethane to obtain 50mg / ml; Injection: 17ml / needle. compound d 1H NMR(400MHz,DMSO)δ 11.98(s,1H),6.67(s,2H),5.60(s,2H),3.30-3.19(m,1H),3.03-2.93(m,1H),2.90-2.70(m,1H),2.35(dtd,1H),1.69(ddt,1H). LCMS m / z=329.1[M+1]+ Compound d-1 1H NMR(400MHz,DMSO)δ 11.98(s,1H),6.68(d,2H),5.60(s,2H),3.29-3.18(m,1H),2.97(tdd,1H),2.90-2.72(m,1H),2.35(dtd,1H),1.69(ddt,1H). LCMS m / z=329.0[M+1]+ Step 4: Preparation of compound e (R,Z)-(2-cyano-2-(2-(3,5-dichloro-4-)((7-(methyl-d3)-1-sideoxy-2,5,6,7-tetrahydro-1H-cyclopentyl[d]tadalafil) -4-yl)oxy)phenyl)hydrazine-4-acetylated)aminocarbamate ethyl ester Ethyl(R,Z)-(2-cyano-2-(2-(3,5-dichloro-4-((7-(methyl-d3)-1-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[d]pyridazin-4-yl)oxy)phenyl)hydrazineylidene)acetyl)carbamate e In a 100L reactor, 16.0 kg of acetic acid, 4.0 kg of purified water, and 2.0 kg of compound d were added with stirring. The mixture was cooled to 0±5℃, and then 2.36 kg of hydrochloric acid was added. After the addition was complete, the mixture was kept at 0±5℃ and stirred for approximately 20 minutes. Sodium nitrite solution (0.5 kg of sodium nitrite dissolved in 1.0 kg of purified water) was added dropwise while maintaining the temperature at 0±5℃. After the addition was complete, the mixture was kept at 0±5℃ and reacted for 2 hours. Sodium acetate solution (1.5 kg of sodium acetate dissolved in 6.0 kg of purified water) was added dropwise while maintaining the temperature at 5±5℃. After the addition was complete, 0.99 kg of N-cyanoaceturane was added. After the addition was complete, the mixture was heated to 10±5℃ and reacted for approximately 2 hours. Samples were taken for HPLC monitoring, and thereafter, samples were taken approximately every 2 hours. The content of compound d was determined by HPLC. 1.0%, stop the reaction. After the reaction was complete, the temperature was maintained at 10±5℃, and 30.0 kg of purified water was added to the reactor. After the addition was complete, the temperature was maintained at 10±5℃ and stirring was continued for 1 hour. The mixture was then filtered, and the filter cake was washed with 3.0 kg of purified water. The filter cake and 12.6 kg of anhydrous ethanol were added to a 100 L reactor, and the temperature was raised to 50±5℃ and stirred for about 1 hour. The temperature was then lowered to 20±5℃, and the mixture was stirred for 0.5 hours. The mixture was then filtered, and the filter cake was washed once with 1.26 kg of anhydrous ethanol. The filter cake was stored at 55±5℃ under vacuum. The material was dried at -0.07 MPa for about 17 hours, and compound e was obtained with a weight of 2.6327 kg. 1H NMR(400MHz,DMSO)δ 12.08(d,2H),10.88(s,1H),7.99(s,2H),4.21(q,2H),3.30-3.17(m,1H),3.08- 2.95(m,1H),2.95-2.80(m,1H),2.38(ddd,1H),1.78-1.63(m,1H),1.28(t,3H). LCMS m / z=496.1[M+1]+ Step 5: Preparation of Compound I (R)-2-(3,5-dichloro-4-((7-(methyl-d3)-1-sideoxy-2,5,6,7-tetrahydro-1H-cyclopentanol[d] -4-yl)oxy)phenyl)-3,5-dioxy-2,3,4,5-tetrahydro-1,2,4-tris( ...tetrahydro-1,2,4-tris(2,3,4,5-tetrahydro-1,2,4-tetrahydro-1,2,4-tris(2,3,4,5- -6-formonitrile (R)-2-(3,5-dichloro-4-((7-(methyl-d3)-1-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[d]pyridazin-4-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile In a 100L reactor, 12.40 kg of N,N-dimethylacetamide, 2.6269 kg of compound e, and 0.54 kg of sodium acetate were added with stirring. After the addition was complete, the temperature was raised and maintained at 115±5℃ for approximately 2 hours. Samples were then taken for HPLC monitoring. Subsequently, samples were taken approximately every 2 hours to determine the content of compound e using HPLC. 1.0%, stop the reaction. After the reaction is complete, the temperature is lowered to 60±5℃, and 0.788 kg of purified water is added to the reaction solution. After the addition is complete, the mixture is filtered while hot, and the reaction solution is quickly added to 13.66 kg of purified water. The temperature is then lowered to 10±5℃. The mixture is filtered, and 20 L of dimethyl sulfoxide is added to the filter cake. The mixture is heated to dissolve the precipitate, and 800 L of acetone is added. The mixture is stirred for 0.5–1 h, filtered, and the filter cake is then incubated at 55±5℃ under vacuum. Drying at -0.07 MPa for about 20 hours yields compound (I) in an amorphous form, weighing 1.56 kg. 1H NMR(400MHz,DMSO)δ 13.26(s,1H),12.09(s,1H),7.79(s,2H),3.32-3.24(m,1H),3.10-2.99(m,1H),2.96-2.88(m,1H),2.45-2.31(m,1H),1.77-1.69(m,1H). LCMS m / z=450.0[M+1]+. Example 2: Preparation of Crystal Form A of Compound I 200 mg of compound I prepared in Example 1 was added to 10 ml of water and stirred at room temperature for 3-5 hours. The mixture was then filtered to obtain crystal form A. Crystal form A of compound I was characterized by XRPD, DSC, and TGA. The XRPD plot is shown in Figure 1, and the DSC and TGA plots are shown in Figure 2. TGA results showed that crystal form A experienced a 7.4% weight loss upon heating to 130 °C and decomposed above 315 °C. DSC results showed that crystal form A exhibited an endothermic signal corresponding to the TGA weight loss at approximately 99 °C and an exothermic peak for crystal transformation at approximately 171 °C. Thermal crystal transformation experiments indicated that crystal form A remained crystal form A upon heating to 150 °C and transformed into crystal form C upon heating to 300 °C. NMR results showed no solvent residue in the sample. Water content testing showed that crystal form A contained 8.2% water, consistent with the weight loss observed by TGA. In conclusion, crystal form A is a dihydrate. The XRPD diffraction peaks of crystal form A are listed in the table below: Example 3: Preparation of crystal form B of compound I Approximately 150 mg of the compound of formula I obtained in Example 1 was added to 4-methyl-2-pentanone until dissolved, and n-hexane was added dropwise until a solid precipitated. The mixture was stirred for 3-5 hours, filtered, and the resulting solid was dried overnight at room temperature to obtain crystalline form B. Crystalline form B of the compound of formula I was characterized by XRPD, DSC, and TGA. The XRPD plot is shown in Figure 3, and the DSC and TGA plots are shown in Figure 4. The TGA results showed that crystalline form B experienced an 8.8% weight loss during heating to 200°C and may decompose above 315°C. The DSC results showed that crystalline form B exhibited an endothermic signal corresponding to the weight loss at approximately 139°C. NMR results showed no change in the compound structure. A solvent peak for cyclohexane was observed at 1.40 ppm, and solvent peaks for 4-methyl-2-pentanone were observed at 0.85 ppm, 1.99 ppm, 2.06 ppm, and 2.30 ppm. Based on the integration results, the ratio of the compound to cyclohexane was 1:0.05, and the ratio of the compound to 4-methyl-2-pentanone was 1:0.4. The estimated mass percentage of 4-methyl-2-pentanone was approximately 8.5%, consistent with the weight loss observed by TGA. In conclusion, crystal form B is a solvate of 4-methyl-2-pentanone, and the ratio of the compound to 4-methyl-2-pentanone is 1:0.4. The XRPD diffraction peaks of crystal form B are listed in the table below: Example 4: Preparation of crystal form C of the compound shown in Formula I Approximately 150 mg of the compound of formula I obtained in Example 1 was added to 3.0 mL of chloroform, stirred at 50 °C for one day, centrifuged, and the resulting solid was vacuum dried overnight at room temperature to obtain crystalline form C. Crystalline form C of compound of formula I was characterized by XRPD, DSC, and TGA. The XRPD plot is shown in Figure 5, and the DSC and TGA plots are shown in Figure 6. The TGA results showed that crystalline form C experienced a 0.8% weight loss during heating to 200 °C and may decompose above 315 °C. The DSC results showed that crystalline form C exhibited an endothermic signal corresponding to the weight loss observed in the TGA at around 70 °C, and no melting endothermic signal was observed before 300 °C. In conclusion, crystalline form C is an amorphous form. The XRPD diffraction peaks of crystal form C are listed in the table below: Example 5: Preparation of crystal form D of the compound shown in Formula I 20 mg of compound I prepared in Example 1 was added to ethylene glycol monomethyl ether until dissolved, and toluene was added dropwise until a solid precipitated. The mixture was stirred for 3-5 hours, centrifuged, and the resulting solid was dried under vacuum overnight at room temperature to obtain crystal form D. Crystal form D of compound I was characterized by XRPD, DSC, and TGA. The XRPD plot is shown in Figure 7, and the DSC and TGA plots are shown in Figure 8. TGA results showed that crystal form D experienced a 7.6% weight loss upon heating to 150°C, an 8.5% weight loss at 150-200°C, and may decompose above 330°C. DSC results showed endothermic peaks corresponding to the weight loss at approximately 139°C and 177°C. NMR results showed that the compound structure remained unchanged, with solvent peaks for toluene visible at 2.30 ppm, 7.18 ppm, and 7.24 ppm. Based on the integration results, the estimated mass percentage was approximately 14.0%, consistent with the weight loss observed in TGA. In summary, crystal form D is a toluene solvate, and the ratio of the compound to toluene is 1:0.4. The XRPD diffraction peaks of crystal form D are listed in the table below: Example 6: Preparation of crystal form E of the compound shown in Formula I Take 55 mg of the compound of formula I prepared in Example 1, add N,N-dimethylformamide (DMF) until dissolved, add water dropwise until a solid precipitates, stir for 3-5 h, centrifuge, and dry the resulting solid under vacuum overnight at room temperature to obtain crystal form E. Crystal form E of the compound of formula I was characterized by XRPD, DSC, and TGA. The XRPD diagram is shown in Figure 9, and the DSC and TGA diagrams are shown in Figure 10. TGA results show that crystal form E experiences a 10.2% weight loss when heated to 120℃, an 11.2% weight loss at 120-180℃, and may decompose above 330℃. DSC results show that crystal form E has endothermic peaks corresponding to the weight loss observed in TGA at approximately 112℃ and 157℃. Thermal transformation experiments show that crystal form E transforms into crystal form C after solvent removal. NMR results showed no change in the compound structure, with DMF solvent peaks visible at 2.73 ppm, 2.89 ppm, and 7.95 ppm. Based on the integration results, the estimated mass fraction is approximately 20.5%, consistent with the weight loss observed by TGA. In conclusion, crystal form E is a DMF solvate, with a compound-to-DMF ratio of 1:0.8. The XRPD diffraction peaks of crystal form E are listed in the table below: Example 7: Preparation of crystal form F of the compound shown in Formula I 20 mg of compound I prepared in Example 1 was added to ethylene glycol methyl ether until dissolved, and acetone was added dropwise until a solid precipitated. The mixture was stirred for 3-5 hours, centrifuged, and the resulting solid was dried under vacuum overnight at room temperature to obtain crystal form F. Crystal form F of compound I was characterized by XRPD, DSC, and TGA. The XRPD plot is shown in Figure 11, and the DSC and TGA plots are shown in Figure 12. TGA results showed that crystal form F experienced an 11.3% weight loss when heated to 150°C, and may decompose above 330°C. DSC results showed that crystal form F had an endothermic signal corresponding to the TGA weight loss around 125-180°C, and an exothermic peak indicating crystal transformation around 204°C. The thermal crystal transformation experiment showed that crystal form F transformed into crystal form C after heating to 230°C. NMR results showed that the compound structure did not change, and a solvent peak of acetone was visible at 2.09 ppm. Based on the integration results, the estimated mass percentage was approximately 10.0%, consistent with the weight loss observed in TGA. In summary, crystal form F is an acetone solvate, and the ratio of the compound to acetone is 1:1. The XRPD diffraction peaks of crystal form F are listed in the table below: Example 8: Preparation of crystal form G of the compound shown in Formula I 20 mg of compound I prepared in Example 1 was added to ethylene glycol methyl ether until dissolved, and ethyl acetate was added dropwise until a solid precipitated. The mixture was stirred for 3-5 hours, centrifuged, and the resulting solid was dried under vacuum overnight at room temperature to obtain crystal form G. Crystal form G of compound I was characterized by XRPD, DSC, and TGA. The XRPD plot is shown in Figure 13, and the DSC and TGA plots are shown in Figure 14. TGA results showed that crystal form G experienced a 16.2% weight loss upon heating to 200°C and may decompose after 330°C. DSC results showed an endothermic signal corresponding to the TGA weight loss at approximately 152°C. NMR results showed no structural change in the compound, with solvent peaks for ethyl acetate visible at 1.16 ppm, 1.99 ppm, and 4.03 ppm. Based on the integration results, the estimated mass fraction was approximately 15.0%, consistent with the TGA weight loss. In conclusion, crystal form G is an ethyl acetate solvate, and the ratio of the compound to ethyl acetate is 1:1. The XRPD diffraction peaks of crystal form G are listed in the table below: Example 9: Preparation of crystal form H of the compound shown in Formula I Take 55 mg of the compound of formula I prepared in Example 1, add dimethyl sulfoxide until dissolved, add water dropwise until a solid precipitates, stir for 3-5 h, centrifuge, and dry the resulting solid under vacuum overnight at room temperature to obtain crystalline form H. The crystalline form H of the compound of formula I was characterized by XRPD, DSC, and TGA. The XRPD chromatogram is shown in Figure 15, and the DSC and TGA chromatograms are shown in Figure 16. The TGA results show that crystalline form H loses 15.2% of its weight when heated to 210 °C, and may decompose after 320 °C. The DSC results show that crystalline form H has an endothermic signal corresponding to the weight loss observed in TGA at 160-230 °C. The NMR results show that the compound structure remains unchanged, and a solvent peak of DMSO is visible at 2.54 ppm. Based on the integration results, the estimated mass percentage is approximately 15.0%, consistent with the weight loss observed in TGA. In conclusion, crystalline form H is a DMSO solvate, and the ratio of the compound to DMSO is 1:1. The XRPD diffraction peaks of crystal form H are listed in the table below: Example 10: Preparation of Crystal Form I of the Compound Shown by Formula I Take 55 mg of the compound of formula I (crystal form A), add isopropyl acetate, stir at 50 °C for 10-15 h, centrifuge, and dry the resulting solid under vacuum overnight at room temperature to obtain crystal form I. Crystal form I of the compound of formula I was characterized by XRPD, DSC, and TGA, as shown in Figures 17-18. TGA results showed that crystal form I experienced a 17.7% weight loss upon heating to 200 °C, and may decompose after 315 °C. DSC results showed an endothermic peak corresponding to the weight loss observed in TGA at approximately 158 °C. NMR results showed no change in the compound structure, with solvent peaks of isopropyl acetate visible at 1.17 ppm, 1.96 ppm, and 4.84 ppm. Based on the integration results, the estimated mass percentage is approximately 17.6%, consistent with the weight loss observed in TGA. In conclusion, crystal form I is an isopropyl acetate solvate, with a compound-to-isopropyl acetate ratio of 1:0.9. The XRPD diffraction peaks of crystal form I are listed in the table below: Example 11 Preparation of crystal form J of the compound shown in Formula I 55 mg of the compound in crystal form A (Formula I) was added to acetonitrile and stirred at 50 °C for 10–15 h. After centrifugation, the resulting solid was vacuum dried overnight at room temperature to obtain crystal form J. Crystal form J of the compound in Formula I was characterized by XRPD, DSC, and TGA, as shown in Figures 19–20. TGA results showed that crystal form J experienced a 4.1% weight loss upon heating to 150 °C and may decompose after 320 °C. DSC results showed an endothermic signal corresponding to the TGA weight loss at approximately 133 °C and an exothermic signal of crystal transformation at approximately 157 °C. The thermal crystal transformation experiment showed that crystal form J transformed into crystal form C after solvent removal. NMR results showed that the compound structure remained unchanged, and a solvent peak for acetonitrile was visible at 2.07 ppm. Based on the integration results, the ratio of the compound to acetonitrile was calculated to be 1:0.1, with a rough estimated mass percentage of approximately 1.29%. Example 12 Preparation of crystal form K of the compound shown in Formula I 55 mg of compound I prepared in Example 1 was added to dioxane until dissolved, and n-heptane was added dropwise until a solid precipitated. The mixture was stirred for 3-5 hours, centrifuged, and the resulting solid was dried under vacuum overnight at room temperature to obtain crystal form K. Crystal form K of compound I was characterized by XRPD, DSC, and TGA, as shown in Figures 21-22. TGA results showed that crystal form K experienced a 15.6% weight loss upon heating to 210 °C and may decompose after 315 °C. DSC results showed that crystal form K exhibited an endothermic signal corresponding to the TGA weight loss around 185-205 °C and an exothermic peak for recrystallization around 254 °C. Thermal conversion experiments showed that crystal form K transformed into crystal form C upon heating to 260 °C. NMR results showed that the compound structure remained unchanged, and a solvent peak for dioxane was visible at 3.57 ppm. Based on the integration results, the approximate mass percentage was calculated to be approximately 14.3%, consistent with the weight loss observed in TGA. In summary, crystal form K is a dioxane solvate, and the ratio of the compound to dioxane is 1:0.9. The XRPD diffraction peaks of crystal form K are listed in the table below: Example 13 Preparation of crystal form L of the compound shown in Formula I 40 mg of compound I prepared in Example 1 was added to dioxane until dissolved, water was added dropwise until a solid precipitated, the mixture was stirred for 3-5 hours, centrifuged, and the resulting solid was vacuum dried overnight at room temperature to obtain crystal form L. Crystal form L of compound I was characterized by XRPD, DSC, and TGA, as shown in Figures 23-24. TGA results showed that crystal form L experienced a 7.3% weight loss upon heating to 100°C and may decompose after 330°C. DSC results showed that crystal form L had an endothermic peak corresponding to the TGA weight loss at around 80°C and an exothermic peak indicating crystal transformation at around 158°C. Thermal crystal transformation experiments showed that crystal form L transformed into crystal form A upon heating to 100°C and into crystal form C upon heating to 190°C. NMR results showed that the compound structure remained unchanged, and a solvent peak for dioxane was visible at 3.57 ppm, with a rough estimated mass percentage of approximately 0.6%. Water content testing results showed that crystal form L had a water content of 8.7%, consistent with the weight loss of TGA. In conclusion, crystal form L is a dihydrate. The XRPD diffraction peaks of crystal form L are listed in the table below: Example 14 Preparation of crystal form M of the compound shown in Formula I 40 mg of compound I prepared in Example 1 was added to ethylene glycol dimethyl ether until dissolved, and chloroform was added dropwise until a solid precipitated. The mixture was stirred for 3-5 hours, centrifuged, and the resulting solid was vacuum-dried overnight at room temperature to obtain crystalline form M, which had slightly poor crystallinity. Crystalline form M of compound I was characterized by XRPD, DSC, and TGA, as shown in Figures 25-26. TGA results showed that crystalline form M experienced a 10.6% weight loss upon heating to 200 °C and may decompose after 315 °C. DSC results showed that crystalline form M exhibited an exothermic transformation peak around 228 °C. Thermal transformation experiments indicated that crystalline form M transformed into crystalline form C upon heating to 260 °C. NMR results showed that the compound structure remained unchanged. A solvent peak for chloroform was observed at 8.32 ppm, and solvent peaks for 4-methyl-2-pentanone were observed at 0.85 ppm, 1.99 ppm, 2.06 ppm, and 2.30 ppm. Based on the integration results, the ratio of the compound to chloroform was calculated to be 1:0.2, and the ratio of the compound to 4-methyl-2-pentanone was also calculated to be 1:0.2. Example 15 Preparation of crystal form N of the compound shown in Formula I 40 mg of compound I prepared in Example 1 was added to ethylene glycol dimethyl ether until dissolved, and acetonitrile was added dropwise until a solid precipitated. The mixture was stirred for 3-5 hours, centrifuged, and the resulting solid was vacuum dried overnight at room temperature to obtain crystalline form N. Crystalline form N of compound I was characterized by XRPD, DSC, and TGA, as shown in Figures 27-28. TGA results showed that crystalline form N experienced a 5.6% weight loss upon heating to 150°C and may decompose after 315°C. DSC results showed that crystalline form N exhibited an endothermic signal corresponding to the TGA weight loss around 100-160°C and a transcrystallization exothermic peak around 204°C. Thermal transcrystallization experiments indicated that crystalline form N transformed into the less crystallizable crystalline form C upon heating to 235°C. NMR results showed that the compound structure remained unchanged, and a solvent peak for acetonitrile was visible at 2.07 ppm. Based on the integration results, the estimated mass percentage was approximately 5.0%, consistent with the weight loss observed in TGA. In summary, crystal form N is an acetonitrile solvate, and the ratio of the compound to acetonitrile is 1:0.6. The XRPD diffraction peaks of crystalline N are listed in the table below: Example 16 Preparation of crystal form O of the compound shown in Formula I 100 mg of compound I prepared in Example 1 was added to 0.5 ml of N,N-dimethylformamide, heated until dissolved, and methanol was added dropwise until a solid precipitated. The mixture was then slowly cooled to room temperature, stirred for 3-5 hours, centrifuged, and the resulting solid was vacuum dried overnight at room temperature to obtain crystalline form O. Crystalline form O of compound I was characterized by XRPD, DSC, and TGA, as shown in Figures 29-30. TGA results showed that crystalline form O experienced a 4.7% weight loss upon heating to 110 °C, a 9.8% weight loss at 110-150 °C, and may decompose after 315 °C. DSC results showed that crystalline form O exhibited endothermic signals corresponding to the TGA weight loss at 80-110 °C and 130-160 °C. NMR results showed that the compound structure remained unchanged, with DMF solvent peaks visible at 2.73 ppm, 2.89 ppm, and 7.95 ppm. Based on the integration results, the estimated mass percentage was approximately 11.7%. In summary, crystal form O is a DMF solvate, and the ratio of the compound to DMF is 1:0.8. The XRPD diffraction peaks of crystalline O are listed in the table below: Example 17 Preparation of crystal form P of the compound shown in Formula I 100 mg of compound I prepared in Example 1 was added to 1 ml of methanol, heated to reflux, and 1 ml of toluene was added dropwise. The mixture was slowly cooled to room temperature, stirred for 3-5 hours, centrifuged, and the resulting solid was vacuum dried overnight at room temperature to obtain crystalline form P. Crystalline form P of compound I was characterized by XRPD, DSC, and TGA, as shown in Figures 31-32. TGA results showed that crystalline form P experienced an 8.0% weight loss upon heating to 150 °C and may decompose after 315 °C. DSC results showed an endothermic signal corresponding to the TGA weight loss in crystalline form P between 75-130 °C. NMR results showed no structural change in the compound; solvent peaks for toluene were observed at 2.30 ppm, 7.18 ppm, and 7.24 ppm, and solvent peaks for methanol were observed at 3.17 ppm and 4.10 ppm. Based on the integration results, the methanol content was roughly estimated to be approximately 1.7%. Water content testing showed that crystalline form P contained 8.2% water, consistent with the weight loss observed by TGA. In summary, crystal form P is a dihydrate. The XRPD diffraction peaks of crystalline form P are listed in the table below: Example 18 Preparation of crystal form Q of the compound shown in Formula I 100 mg of the compound in crystal form A (Formula I) was added to 1 ml of tetrahydrofuran. The mixture was stirred at room temperature for 3-5 hours, centrifuged, and the resulting solid was dried under vacuum overnight at room temperature to obtain crystal form Q. Crystal form Q of the compound in Formula I was characterized by XRPD, DSC, and TGA, as shown in Figures 33-34. TGA results showed that crystal form Q experienced a 13.2% weight loss upon heating to 200 °C, and decomposition may occur above 330 °C. DSC results showed an endothermic signal corresponding to the weight loss observed in TGA before 190 °C. NMR results showed no structural change in the compound, with solvent peaks of tetrahydrofuran visible at 1.75 ppm and 3.59 ppm. Based on the integration results, the ratio of the compound to tetrahydrofuran was calculated to be 1:0.6, with a rough estimated mass percentage of approximately 8.4%. In conclusion, crystal form Q is likely a tetrahydrofuran solvate containing water of crystallization. Example 19 Preparation of crystal form R of the compound shown in Formula I 100 mg of compound I prepared in Example 1 was added to dioxane until dissolved, and then diethyl ether was added dropwise until a solid precipitated. The mixture was stirred for 3-5 hours, centrifuged, and the resulting solid was dried under vacuum overnight at room temperature to obtain crystalline form R. Crystalline form R of compound I was characterized by XRPD, DSC, and TGA, as shown in Figures 35-36. TGA results showed that crystalline form R experienced a 15.6% weight loss upon heating to 200 °C and may decompose after 315 °C. DSC results showed an endothermic signal corresponding to the weight loss observed in TGA at approximately 185 °C. Thermal transformation experiments indicated that crystalline form R transformed into crystalline form C after solvent removal. NMR results showed no change in the compound structure. A solvent peak for dioxane was observed at 3.57 ppm, and solvent peaks for diethyl ether were observed at 1.09 ppm and 3.38 ppm. Based on the integration results, the estimated mass fraction was approximately 14.7%, with a compound-to-ether ratio of 1:0.3, and an estimated mass fraction of approximately 4.1%. In conclusion, crystal form R is a dioxane solvate, and the compound-to-dioxane ratio is 1:0.9. Example 20: Preparation of crystal form S of the compound shown in Formula I 100 mg of compound I prepared in Example 1 was added to 0.5 ml of dimethyl sulfoxide, heated to a clear solution, cooled to room temperature, and ethanol was added dropwise until a solid precipitated. The mixture was stirred for 3-5 hours, centrifuged, and the resulting solid was vacuum-dried overnight at room temperature to obtain crystal form S. Crystal form S of compound I was characterized by XRPD, DSC, and TGA, as shown in Figures 37-38. TGA results showed that crystal form S experienced a 15.0% weight loss upon heating to 230 °C and may decompose after 315 °C. DSC results showed an endothermic signal corresponding to the TGA weight loss in crystal form S around 190-230 °C. NMR results showed no structural change in the compound, and a solvent peak for DMSO was visible at 2.54 ppm. Based on the integration results, the estimated mass percentage was approximately 14.2%, consistent with the weight loss observed in TGA. In conclusion, crystal form S is a DMSO solvate, with a compound-to-DMSO ratio of 1:1. The XRPD diffraction peaks of crystal form S are listed in the table below: Example 21 Preparation of crystal form T of the compound shown in Formula I 100 mg of compound I prepared in Example 1 was dissolved in 4-methyl-2-pentanone and allowed to evaporate at room temperature until a solid precipitated. The solid was centrifuged and dried under vacuum overnight at room temperature to obtain crystal form T. Crystal form T of compound I was characterized by XRPD, DSC, and TGA, as shown in Figures 39-40. TGA results showed that crystal form T experienced a 9.7% weight loss upon heating to 130 °C, an 8.1% weight loss between 130-200 °C, and decomposed after 315 °C. DSC results showed that crystal form T exhibited an endothermic signal corresponding to the weight loss observed in TGA between 100-170 °C. NMR results showed no structural change in the compound, with solvent peaks of 4-methyl-2-pentanone visible at 0.85 ppm, 1.99 ppm, 2.06 ppm, and 2.30 ppm. Based on the integration results, the estimated mass percentage was 18.0%, consistent with the weight loss observed in TGA. In summary, crystal form T is a solvate of 4-methyl-2-pentanone, and the ratio of the compound to 4-methyl-2-pentanone is 1:1. The XRPD diffraction peaks of crystal form T are listed in the table below: Example 22 Preparation of crystal form U of the compound shown in Formula I 100 mg of compound I prepared in Example 1 was added to 1 ml of methanol, heated to reflux, and 1 ml of acetonitrile was added dropwise. The mixture was slowly cooled to room temperature, stirred for 3-5 hours, centrifuged, and the resulting solid was vacuum dried overnight at room temperature to obtain crystalline form U. Crystalline form U of compound I was characterized by XRPD, DSC, and TGA, as shown in Figures 41-42. TGA results showed that crystalline form U experienced an 8.1% weight loss upon heating to 200 °C and decomposed after 250 °C. DSC results showed an endothermic signal corresponding to the TGA weight loss at approximately 80-150 °C and an exothermic signal of crystal transformation at 155-200 °C. During the experiment, it was found that crystalline form U transformed into crystalline form L after 3 days at room temperature; thermal crystal transformation experiments showed that crystalline form U transformed into crystalline form C upon heating to 250 °C. NMR results showed that the compound structure remained unchanged, and a solvent peak of acetonitrile was visible at 2.07 ppm; based on the integration results, the estimated mass percentage was approximately 5.2%. In summary, crystal form U is an acetonitrile solvate, and the ratio of the compound to acetonitrile is 1:1. Example 23 Preparation of crystal form V of the compound shown in Formula I 100 mg of compound I prepared in Example 1 was added to 1 ml of chloroform and 1 ml of ethanol, stirred at room temperature for 10-15 h, centrifuged, and the resulting solid was vacuum dried overnight at room temperature to obtain crystal form V. Crystal form V of compound I was characterized by XRPD, DSC, and TGA, as shown in Figures 43-44. TGA results showed that crystal form V experienced a 3.4% weight loss upon heating to 200 °C and decomposed after 315 °C. DSC results showed no significant heat flow signal in crystal form V before 300 °C. Thermal conversion experiments showed that crystal form V remained crystal form V upon heating to 150 °C. TGA results of the thermally converted sample showed a 1.6% weight loss upon heating to 150 °C. NMR results showed no change in the compound structure, with a solvent peak of chloroform visible at 8.32 ppm; the ratio of compound to chloroform was calculated to be 1:0.1 based on the integration results. In conclusion, crystal form V is anhydrous. The XRPD diffraction peaks of crystal form V are listed in the table below: Example 24 Preparation of crystal form W of the compound shown in Formula I 20 mg of compound I prepared in Example 1 was dissolved in ethylene glycol monomethyl ether until completely dissolved. The solution was then allowed to diffuse in the ether under gas phase. The resulting solid was dried under vacuum overnight at room temperature to obtain crystal form W. Crystal form W of compound I was characterized by XRPD, as shown in Figure 45. NMR results showed no change in the compound structure. Solvent peaks for ether were observed at 1.09 ppm and 3.38 ppm, and solvent peaks for ethylene glycol monomethyl ether were observed at 3.24 ppm, 3.48 ppm, and 4.56 ppm. Based on the integration results, the ratio of compound to ether was 1:0.3, with a rough estimated mass percentage of approximately 3.7% and approximately 10.1%. In conclusion, crystal form W is a solvate of ethylene glycol monomethyl ether, and the ratio of compound to ethylene glycol monomethyl ether is 1:0.7. The XRPDs of crystal forms F, Q, R, S, U, and W were found to be quite similar, suggesting that these six crystal forms are isomorphous solvates. Example 25 Preparation of crystal form X of the compound shown in Formula I Take 200 mg of the compound of formula I, crystal form E, add 1 ml of toluene, stir at 50-60 °C for 10-15 h, filter, and dry the resulting solid under vacuum overnight at room temperature to obtain crystal form X. The crystal form X of the compound of formula I is characterized by XRPD, as shown in Figure 46. Example 26 Preparation of crystal form Y of the compound shown in Formula I Take 200 mg of the compound G (formula I), add 1 ml of acetonitrile, stir at 50-60 °C for 10-15 h, filter, and dry the resulting solid under vacuum overnight at room temperature to obtain crystal form Y. The crystal form Y of the compound shown in Formula I is characterized by XRPD, as shown in Figure 47. Example 27 Preparation of crystal form Z of the compound shown in Formula I 200 mg of compound I prepared in Example 1 was added to 1 ml of water and 1 ml of N,N-dimethylformamide. The mixture was stirred at room temperature for 10-15 h, filtered, and the resulting solid was vacuum dried overnight at room temperature to obtain crystal form Z. Crystal form Z of compound I was characterized by XRD, DSC, and TGA, as shown in Figures 48-49. TGA results showed that crystal form Z experienced a 0.5% weight loss upon heating to 100 °C, a 13.3% weight loss at 100-200 °C, and decomposed after 330 °C. DSC results showed that crystal form Z exhibited endothermic signals corresponding to the TGA weight loss at 50-80 °C and 110-180 °C. NMR results showed that the compound structure remained unchanged, with DMF solvent peaks visible at 2.73 ppm, 2.89 ppm, and 7.95 ppm. Based on the integration results, the estimated mass percentage was 14.0%, consistent with the weight loss observed by TGA. In summary, crystal form Z is a solvate of DMF, and the ratio of the compound to DMF is approximately 1:0.9. The XRPD diffraction peaks of crystal form Z are listed in the table below: Thermal crystallization test Using different crystal forms as raw materials, the solids were heated to the target temperature using a hot stage and held at that temperature for 1 minute. After cooling to room temperature, XRPD tests were performed on the solids, and the results are shown in the table below. Thermal conversion results The results showed that many crystal forms transformed into crystal form C after heating. Crystal form C is a more stable crystal form at high temperatures, which is very useful as an active ingredient in pharmaceutical preparations. The active ingredient is not easily transformed by heat during the preparation process, thus affecting its bioavailability and other parameters. It is stable even when stored at temperatures above room temperature. Dynamic moisture adsorption-desorption analysis was performed using DVS Intrinsic (SMS, UK). The test employed a gradient mode with humidity variations of 50%-95%-0%-50%. Within the 0% to 90% range, each gradient represented a 10% change in humidity. The gradient endpoint was determined using the dm / dt method, with a dm / dt value less than 0.002% maintained for 10 minutes as the endpoint. After the test, XRPD analysis was performed on the samples to confirm whether the solid form changed. The DVS results are shown in Figure 50. The DVS results show that crystalline C gained 0.20% weight at 95% humidity and lost 0.13% weight at 0% humidity, indicating that crystalline C has almost no hygroscopicity. XRPD results show that the sample did not undergo a change in crystal form after the DVS test. As an amorphous form, crystalline C will not absorb moisture and transform into a crystalline form under high humidity conditions, which is highly advantageous for pharmaceutical preservation and formulation processes. Stability Study Stability Test 1 Approximately 20 mg of sample was weighed and placed in a weighing bottle. The bottle was then subjected to high temperature (60℃), high humidity (25℃, 92.5% RH), light (25℃, 4500 Lux), and accelerated conditions (40℃, 75% RH), respectively. Samples were taken at 7 and 15 days for XRPD characterization. Figure 51 shows the XRPD results, indicating that crystal form C remained stable for 15 days under all conditions (high temperature, high humidity, light, and accelerated conditions) without undergoing any crystal form transformation. Stability Test 2 The crystalline C sample was packaged in a double-layer pharmaceutical low-density polyethylene bag as the inner packaging material and a polyester / aluminum / polyethylene pharmaceutical composite bag as the outer packaging material. Related substances were determined by HPLC at 40℃±2℃ and 75%RH±5%RH for 0 months, 1 month, 2 months, 3 months and 6 months respectively. The results are shown in the table below. The results showed that crystal form C maintained good stability within 6 months under the conditions of 40℃±2℃ and 75%RH±5%RH, and no significant increase in related substances was observed. Stability test 3 The crystalline C sample was packaged in a double-layer pharmaceutical low-density polyethylene bag as the inner packaging material and a polyester / aluminum / polyethylene pharmaceutical composite bag as the outer packaging material. Related substances were determined by HPLC at 5℃±3℃ in 0 months, 3 months, 6 months, 9 months and 12 months respectively. The results are shown in the table below. The results showed that crystal form C maintained good stability within 12 months at 5℃±3℃, and no significant increase in related substances was observed. Stability test 4 The crystalline C sample was packaged in a double-layer pharmaceutical low-density polyethylene bag as the inner packaging material and a polyester / aluminum / polyethylene pharmaceutical composite bag as the outer packaging material. Related substances were determined by HPLC at 25℃±2℃ and 60%RH±5%RH for 0 months, 3 months, 6 months, 9 months and 12 months respectively. The results are shown in the table below. The results showed that crystal form C maintained good stability within 12 months under the conditions of 25℃±2℃ and 60%RH±5%RH, and no significant increase in related substances was observed. Stability test 5 The crystalline C sample was packaged in a double-layer pharmaceutical low-density polyethylene bag as the inner packaging material and a polyester / aluminum / polyethylene pharmaceutical composite bag as the outer packaging material. Related substances were determined by HPLC at 30℃±2℃ and 65%RH±5%RH for 0 months, 3 months, 6 months, 9 months and 12 months respectively. The results are shown in the table below. The results showed that crystal form C maintained good stability within 12 months under the conditions of 30℃±2℃ and 65%RH±5%RH, and no significant increase in related substances was observed.
Claims
1. A polymorph of a compound of formula I: I, wherein, When n is 0, the polymorph is of crystal form C. Under Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ positions: 11.03°±0.2°, 15.79°±0.2°, 16.97°±0.2°, 23.27°±0.2°, 23.76°±0.2°, and 27.61°±0.2°.
2. The polymorph according to claim 1 also has characteristic diffraction peaks at the following 2θ positions in its X-ray powder diffraction pattern: 14.12°±0.2°, 19.73°±0.2°, 22.51°±0.2°, 25.37°±0.2°, 28.21°±0.2°, and 33.73°±0.2°.
3. The X-ray powder diffraction pattern of the polymorph described in claim 1 or 2 is basically as shown in Figure 5.
4. The polymorph according to claim 1 or 2, wherein the polymorph C has the DSC diagram and / or TGA diagram of FIG6.
5. A pharmaceutical composition comprising a therapeutically effective amount of the polymorph described in any one of claims 1 to 4, and a pharmaceutically acceptable carrier and / or excipient.
6. Use of a polymorph of any one of claims 1 to 4 or a pharmaceutical composition of claim 5 in the preparation of a medicine for treating primary hypercholesterolemia.
Citation Information
Patent Citations
Thyroid hormone receptor agonists and uses thereof
CN111801324A
